ATP1A3, Blocking Peptide

Sodium/potassium-transporting ATPase subunit alpha-3; Na(+)/K(+) ATPase alpha-3 subunit; Na(+)/K(+) ATPase alpha(III) subunit; Sodium pump subunit alpha-3; ATP1A3

For Research Use Only. Not for use in diagnostic procedures.

The synthetic peptide sequence is selected from aa 464-477 of HUMAN ATP1A3

Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Small volumes of ATP1A3 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.

113,059 Da

ATPase Na+/K+ transporting subunit alpha 3

sodium/potassium-transporting ATPase subunit alpha-3

Sodium/potassium-transporting ATPase subunit alpha-3

Na(+)/K(+) ATPase alpha-3 subunit  [Similar Products]

AT1A3_HUMAN

The protein encoded by this gene belongs to the family of P-type cation transport ATPases, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The catalytic subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes an alpha 3 subunit. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]

ATP1A3: This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients. Defects in ATP1A3 are the cause of dystonia type 12 (DYT12); also known as rapid-onset dystonia parkinsonism (RDP). DYT12 is an autosomal dominant dystonia- parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT12 patients develop dystonia and parkinsonism between 15 and 45 years of age. The disease is characterized by an unusually rapid evolution of signs and symptoms. The sudden onset of symptoms over hours to a few weeks, often associated with physical or emotional stress, suggests a trigger initiating a nervous system insult resulting in permanent neurologic disability. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IIC subfamily.

Protein type: Transporter; Endoplasmic reticulum; Membrane protein, multi-pass; Hydrolase; Transporter, ion channel; Membrane protein, integral; EC 3.6.3.9

Chromosomal Location of Human Ortholog: 19q13.31

Cellular Component: endoplasmic reticulum; Golgi apparatus; plasma membrane; sodium:potassium-exchanging ATPase complex; synapse

Molecular Function: chaperone binding; sodium:potassium-exchanging ATPase activity

Biological Process: ATP hydrolysis coupled proton transport; cellular potassium ion homeostasis; cellular sodium ion homeostasis; potassium ion import

Disease: Alternating Hemiplegia Of Childhood 2; Cerebellar Ataxia, Areflexia, Pes Cavus, Optic Atrophy, And Sensorineural Hearing Loss; Dystonia 12

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.